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Background: Localization and differential expression of STAT3 and survivin in can-
cer cells are often related to distinct cellular functions. The involvement of survivin
and STAT3 in gastric cancer has been reported in separate studies but without clear
understanding of their kinetics in cancer progression.
Methods: We examined intracellular distribution of STAT3 and survivin in gastric
adenocarcinoma and compared it with normal and precancer tissues using immuno-
blotting and immunohistochemistry.
Results: Analysis of a total of 156 gastric samples comprising 61 histologically nor-
mal, 30 precancerous tissues (comprising intestinal metaplasia and dysplasia), and 65
adenocarcinomas, collected as endoscopic biopsies from treatment naïve study partic-
ipants, revealed a significant (P < .001) increase in overall protein levels. Survivin
expression was detectable in both cytoplasmic (90.8%) and nuclear (87.7%) compart-
ments in gastric adenocarcinomas lesions. Precancerous dysplastic gastric lesions
exhibited a moderate survivin expression (56.7%) localized in cytoplasmic compart-
ment. Similarly, STAT3 and pSTAT3 expression was detected at high level in gastric
cancer lesions. The levels of compartmentalized expression of survivin and STAT3/
pSTAT3 correlated in precancerous and adenocarcinoma lesions. Although overex-
pression of these proteins was found associated with the tobacco use and alcohol
consumption, their expression invariably and strongly correlated with concurrent
Helicobacter pylori infection. Receiver operating characteristic analysis of nuclear
survivin, STAT3, and pSTAT3 in different study groups showed acceptable positive
and negative predictive values with area under the curve above 0.8 (P < .001).
Conclusion: Overall, our results suggest that overall increase in survivin and STAT3
and their subcellular localization are key determinants of gastric cancer progression,
which can be collectively used as potential disease biomarkers and therapeutic targets
for gastric cancer.iffuse‐type adenocarcinoma; Dys, dysplasia; IC, intestinal‐type adenocarcinoma; IHC, immunohistochemistry; IM,
esearch, Grant/Award Number: 5/13/38/2014 NCDIII‐Eoffice73143; Indian Council of Medical Research–Senior
/2/11/2010/NCD‐III; University of Delhi; Department of Biotechnology, Ministry of Science and Technology,
T/ALCB/2015; Department of Science and Technology, Government of India, Grant/Award Number: Phase II/
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dysplasia, gastric adenocarcinoma, intestinal metaplasia IV, STAT3, survivin1 | INTRODUCTION
According to Globocan 2012, stomach cancer attributable to
Helicobacter pylori infection is the fifth common malignancy in the
world (952 000 cases, 6.8% of the total) and the third leading cause
of cancer death for both sexes worldwide (723 000 deaths, 8.8% of
the total).1 In India, stomach cancer is ranked third (incidence,
43 386; mortality, 40 721) and sixth (incidence, 19 711; mortality,
18 320) in men and women, respectively.1 Regardless of the prevailing
habits of tobacco and alcohol abuse2 and reportedly high prevalence
of infection with pathogenic H. pylori strains3-5 accompanied with
low socioeconomic conditions, the incidence rate of gastric cancer is
reported to be “low” in India.2,6,7 However, these estimates are likely
to be low because of gross underreporting and misdiagnosis of the dis-
ease, particularly in rural areas of India where H. pylori incidence is
high, and which lacks necessary diagnostic and endoscopic facilities.
Management of gastric cancer in India is alarmingly poor; age‐adjusted
relative 10‐year survival ranges from 4% to 15% (average, 6%) in var-
ious regions in India.2,8
Survivin, the smallest member of the Inhibitor of Apoptosis
(IAP) family, plays a critical role in apoptosis, cell division, and cell
migration/metastasis.9 In general, it is associated with poor progno-
sis and low patient survival.10 Prognostic significance of survivin in
gastric carcinogenesis has been investigated but with contradictory
conclusions.11-15 Earlier studies suggested that nuclear survivin is
associated with cell proliferation whereas cytoplasmic and mito-
chondrial survivin is linked to chemoresistance. However, these
results appear to be tissue specific,16 and these discrepancies, also
identified in other malignancies, were attributed to differentially
localized survivin in subcellular compartments as observed in gas-
trointestinal carcinoma and other cancers.15,17 Despite past studies
on survivin in advanced gastric lesions, modulation of its level and
subcellular distribution during the progression of gastric cancer is
currently lacking.
Activation of a transcription factor STAT3 induces the survivin
gene and confers resistance to apoptosis.18 STAT3 activation is medi-
ated by tyrosine phosphorylation at Y705, a converging point for
diverse oncogenic signaling pathways.19 In gastric cancer cells, STAT3
was found to be constitutively active, which promotes cell survival, in
association with survivin.20 H. pylori‐cagA was subsequently shown to
activate STAT3 signaling pathways, which in gastric cancer were cor-
related with survival, metastasis, and poor clinical outcome.21 Interest-
ingly, nuclear translocation of STAT3 in gastric cancer cells can be
triggered by cagA‐mediated clustering of Interleukin (IL) 6 and gp130
membrane receptors.22
In any event, while there is compelling evidence for the presence
of survivin and STAT3, individually in advanced malignant gastric
lesions, their levels and subcellular distribution during gastric cancer
progression were poorly defined. Moreover, their association with
concurrent H. pylori infection or other lifestyle factors like use oftobacco and alcohol is not known. As both of these proteins shuttle
between the cytoplasm and nucleus, a detailed understanding of their
distribution in different subcellular pools warrants investigation
particularly as linked to the disease progression. In the present
investigation, we have therefore assessed collectively modulation
of expression of survivin and STAT3, particularly their subcellular
localization in a subset of tissues representing different stages of
gastric cancer. In addition, we examined the correlation between
survivin expression with STAT3 and with other factors associated
with gastric carcinogenesis such as the presence of cagA+ H. pylori
infection, tobacco usage, or alcohol abuse. Clinical utility of survivin
and STAT3 as potential markers in gastric cancer progression was
also evaluated.Clinical significance
Survivin and STAT3 could be suitable therapeutic targets in preventing
gastric cancer progression, particularly in cases positive for concurrent
H. pylori infection with history of tobacco smoking.2 | MATERIALS AND METHODS
2.1 | Clinical specimens and reagents
A total of 156 gastric samples comprising 61 histologically normal, 30
precancerous tissues, and 65 adenocarcinomas, collected as endo-
scopic biopsies, were obtained prior to any chemo/radiotherapy from
the patients attending Gastroenterology Out‐Patient Department of
Swaroop Rani Hospital, an affiliate to Moti Lal Nehru Medical College,
Allahabad, India, during the period of 2007‐2012. We excluded the
samples with history of prior chemotherapy. As per protocol and pre-
vailing clinical practice, the patients were not followed. Gastric tissues
with type IV intestinal metaplasia (IM, n = 15) and dysplasia (Dys,
n = 15) were grouped as gastric precancerous lesions while diffuse‐
type adenocarcinoma (DC, n = 44) and intestinal‐type adenocarcinoma
(IC, n = 21) were grouped as cancer lesions. Symptomatic, clinically
suspected cases found histologically normal were used as a control.
We also collected gastritis cases (n = 23) as well, although these were
excluded from the study to avoid any bias due to poor sample quality
(study design presented as standard flow diagram). The patients taking
antibiotics, with bleeding ulcers, or suffering acute hemorrhage at
other sites in the upper gastrointestinal track, stomach surgery, or che-
motherapy were excluded. Written informed consent was obtained
from all of the subjects. The study was conducted in accordance with
the principles of Helsinki Declaration. The Institutional Ethics
Committees of Moti Lal Nehru Medical College, Allahabad, and
Institute of Cytology and Preventive Oncology (now renamed as
National Institute of Cancer Prevention and Research), Noida, India,
approved this study prior
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details were taken from clinical record of patients and captured on a
pro forma document. The study questionnaire and the case report
form included details of tobacco use (chewing or smoking) and alcohol
usage. The person with these habits for 6 months or more in the past
at the time of examination (at least one cigarette or bidi/tobacco
chew/alcohol shot for at least 3 d/wk) was grouped as a tobacco user
or alcoholic. A person with more than one habit was grouped under
multiple habits.
A summary of the distribution of study subjects with respect to
their clinico‐epidemiological characteristics included in different dis-
ease groups is presented in Table 1. A part of the clinical sample taken
for diagnostic procedures was used for research purpose. A minimum
2 punches per specimen were collected from the lesion area by endo-
scope‐guided biopsy procedure. One punch of these tissue was imme-
diately and invariably fixed in formalin for routine histopathological
examination and for immunohistochemistry (IHC) analysis while other
punch(es) were collected in chilled 1× phosphate‐buffered saline for
DNA and protein isolation for subsequent molecular studies. TheTABLE 1 Clinico‐epidemiological details of the subjects enrolled in the s
Clinico‐epidemiological Characteristics Normal
Total subjects 61
Gender
Male 42 (68.9%)
Female 19 (31.1%)
Histopathological classification of lesions
Intestinal metaplasia IV …
Dysplasia …
Diffuse‐type adenocarcinoma …
Intestinal‐type adenocarcinoma …
Age in years (median) 07‐85 (40)
Habitsa
Tobacco chewers 28 (45.9%)
Tobacco nonchewers 33 (54.1%)
Tobacco smokers 22 (36.1%)
Tobacco nonsmokers 39 (64%)
Alcoholic 15 (24.6%)
Nonalcoholic 46 (75.4%)
Multiple habits 22 (36.1%)
Helicobacter pylori positive 37 (60.7%)
ureC positive 33 (54.1%)
cagA positive 21 (34.4%)
aTobacco chewing habits include betel quid, areca nut, and/or pan masala use;histopathological grading of precancerous and cancerous lesions was
performed following WHO/Laurén Classification, which was based
on an evaluation of architectural and cytological changes. For each
case, the pathologist recorded the grades and details of criteria on
which the decision was based. All reagents used in the study were
of analytical or molecular biology grade and procured from Sigma‐
Aldrich (St Louis, MO, USA) whereas primary and secondary antibod-
ies and IHC kits were from Santa Cruz Biotechnology, Inc (Texas,
USA) unless specified.
2.1.1 | H. pylori detection
Tissue‐derived DNA was subjected to polymerase chain reaction
(PCR)–based detection of H. pylori infection by analyzing for ureC
and cagA genes using established primers listed in Table S1 (methods
detailed in Methods S1).2.2 | Immunohistochemical analysis for survivin,
STAT3, and pSTAT3 levels
The immunohistochemistry staining (IHC) was performed as described
previously with minor modifications.23,24 Briefly, formalin‐fixed, paraf-
fin‐embedded sections (5 μm) of the gastric tissues were collected on
poly‐L‐lysine–coated slides and then deparaffinized in xylene. After
hydration in a decreasing alcohol gradient, antigen retrieval was per-
formed by pretreatment in a microwave oven for 10 minutes at
800 W and 5 minutes at 480 W in citrate buffer (0.01M, pH = 6.0).
The sections were incubated with hydrogen peroxide (0.3% v/v) in
methanol for 30 minutes to quench the endogenous peroxidase activ-
ity, followed by blocking with 1% bovine serum albumin to preventtudy
Precancer Cancer (Adenocarcinoma)
30 65
17 (56.7%) 42 (64.6%)
13 (43.3%) 23 (35.4%)
15 (50%) …
15 (50%) …
… 44 (67.7%)
… 21 (32.3%)
13‐78 (41.5) 22‐90 (55)
15 (50%) 24 (37%)
15 (50%) 41 (63%)
11 (36.7%) 20 (30.8%)
19 (63.3%) 45 (69.2%)
8 (26.7%) 16 (24.6%)
22 (73.3%) 49 (75.4%)
9 (30%) 16 (24.6%)
28 (93.3%) 34 (52.3%)
27 (90%) 33 (50.7%)
22 (73.3%) 17 (26.2%)
multiple habits include 2 or more of any tobacco and/or alcohol habits.
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monoclonal antisurvivin (SC‐17779), anti‐STAT3 (SC‐483), or anti–
pSTAT3‐Y705 (SC‐8059) antibodies (Santa Cruz Biotechnology) for
16 hours at 4°C. The primary antibodies were detected using the
streptavidin‐biotin complex with the ABC kit (Santa Cruz Biotechnol-
ogy). The slides were stained with diaminobenzidine chromogen for
5 minutes, rinsed in tap water, counterstained in Mayer's hematoxylin,
dehydrated using increasing alcohol gradient and xylene, and mounted
in DPX. Immunoreactivity was visualized in an Olympus microscope.
To avoid any batch variation, we always included a positive control
that was used during standardization of the protein staining and all
samples were stained for a protein at the same time to avoid any bias.
2.3 | Evaluation of immunohistochemical staining
Each slide was evaluated for survivin, STAT3, and pSTAT3 immuno-
staining using a semiquantitative scoring system for both staining
intensity and the percentage of positive epithelial cells.24 The sections
were scored independently by 2 investigators (A.P. and S.C.T.). The
tissue sections were scored on the scale of 0 to 7 based on the
percentage of immunostained cells as <10% = 0; 10‐30% = 1;
30‐50% = 2; 50‐70% = 3; and 70‐100% = 4. Sections were also scored
semiquantitatively on the basis of staining intensity as no‐stain = 0;
mild = 1; moderate = 2; and intense = 3. Finally, a total score was
obtained by adding the scores of percent positivity and intensity. For
intracellular localization of proteins in various compartments, the
nuclear and cytoplasmic staining were scored independently. Less
than 5% cases showed the interobserver discrepancy. In the cases
with score discrepancy between the 2 observers, a third independent
review was performed (V.M.) and a consensus on the final result was
reached. The sections were considered positive if cells showed
immunopositivity in the nucleus or cytoplasm and attained a total
score of 2 or more for survivin and 3 or more for STAT3 and pSTAT3.
2.4 | Total protein isolation and immunoblotting
Total proteins from biopsies and cell lines were isolated and examined
by the method described previously.23,25 Detailed procedures are pro-
vided in Methods S1.
2.5 | Statistical analysis
The IHC data were subjected to statistical analyses using the SPSS sta-
tistics 19.0 software (IBM, New York, USA). Sensitivity and specificity
were calculated and quantified using receiver operating characteristic
analyses. The predictive value was calculated to describe the propor-
tion of correctly classified cases. Based on sensitivity and specificity
values, a cutoff was defined independently for both cytoplasmic and
nuclear immunopositivity for statistical analyses. The systematic and
rigorous assessment of positive and negative predictive values for
markers was conducted as described earlier.26 The relationships
between proteins expression (western blotting and IHC), PCR analysis,
and clinicopathological parameters were tested using chi‐square and
the Fischer exact test. Two‐sided P values were calculated, and P
value of .05 or less was considered significant. The correlation
between positivity for ureC, cagA, survivin, STAT3, and pSTAT3 wasevaluated using Pearson correlation method whereas nonparametric
correlation in the total sample was checked by the Spearman ρ and
Pearson correlation method since the data obtained by the 2 methods
were similar only Pearson correlation is indicated.3 | RESULTS
3.1 | Expression and intracellular localization of
survivin in gastric lesions
Increased level of survivin was detected by immunoblotting in both
DC and IC tissues as compared with the normal tissues (Figure 1A).
Precancerous lesions showed a moderate or low level of survivin.
The cumulative densitometric analysis revealed that these differences
in the level of survivin were statistically significant in different disease
groups (Figure 1B).
To assess intracellular variation and heterogeneity in expression
of survivin within the cells and tissues of the lesion area, correspond-
ing formalin‐fixed gastric tissues were subjected to IHC analysis for
survivin. The box plot analysis of scores for survivin immunostaining
in cytoplasmic and nuclear compartments shows the interquartile
range of distribution and the outliers in respective category
(Figures 1C,D and S1). Histologically normal tissues invariably lacked
survivin expression, both in epithelial cells of gastric glands and in
stromal cells (Figure 1D and Table S2). However, there was sporadic
survivin immunopositivity in a proportion of histologically normal tis-
sues (10/61). During the analysis, we found that survivin‐positive nor-
mal tissues were from individuals who had the habit of tobacco
chewing and simultaneously carried cagA+ H. pylori infection (Table S2).
Intestinal metaplasia and dysplastic lesions showed significantly
increased survivin expression (P < .001) in epithelial cells of gastric
glands compared with normal lesions. Interestingly, a low to moderate
diffused expression of survivin was also observed in the stromal cells
in these dysplastic lesions but not in IM. Cytoplasmic and nuclear
immunopositivity of survivin in precancer lesions was associated with
the multiple habits of the patients (irrespective of the type of habits).
Interestingly, cytoplasmic survivin positivity in precancer was also
strongly associated with cagA+ H. pylori infection (Table S3).
A significant increase in survivin expression was observed in DC
and IC compared to the precancerous lesions. Interestingly, survivin
was diffusely expressed in both cytoplasmic (90.8%) and nuclear
(87.7%) regions of the advanced adenocarcinoma cells compared to
predominant cytoplasmic distribution of survivin in precancerous
lesions. Tobacco usage in any form was found to be invariably associ-
ated with survivin overexpression in both cytoplasmic and nuclear
regions (Table S4). Similarly, all H. pylori‐positive adenocarcinoma
lesions, irrespective of ureC or cagA positivity, were found to be
immunopositive for cytoplasmic and nuclear survivin.
3.2 | Expression and activation of STAT3 in various
grades of gastric biopsies
Next, we examined the levels of total STAT3 and its active form
(pSTAT3‐Y705 or pSTAT3) in different grades of gastric lesions.
Increased level of STAT3 was present in adenocarcinoma tissues
FIGURE 1 Expression and subcellular localization of survivin in human gastric biopsies. A, Representative immunoblots showing level of survivin.
Positive control (Ctrl; HeLa cells), gastric adenocarcinoma cells (AGS) and freshly collected normal (N), intestinal metaplasia (IM), dysplasia (Dys),
diffuse‐type adenocarcinoma (DC), and intestinal‐type adenocarcinoma (IC) tissues. Blots were reprobed for β‐actin, which was used as a loading
control (50 μg of total cellular proteins/lane). B, Mean fold difference in the integrated densitometric values of bands in the immunoblots was
calculated as described below after normalizing the values to β‐actin. Error bars indicate standard deviation. *P value ≤ .001 vs normal, #P
value = .004 vs intestinal metaplasia, and †P value < .05 vs dysplasia. C, Box plots showing distribution of nuclear and cytoplasmic survivin total
scores based on immunohistochemical analysis. Normal, Precancer, and Cancer. Scoring was performed on the scale of 0 to 7 on percent positivity
and intensity of staining as described in Section 2. The outlier samples with their individual score represented as asterisk/dot. D, Representative
immunohistochemical photomicrographs showing expression of survivin. Well‐differentiated IC (WD‐IC), moderately differentiated IC (MD‐IC).
Black arrows = cytoplasmic expression; green arrows = nuclear expression (original magnification, ×200)
PANDEY ET AL. 5 of 11irrespective of their type compared with the normal tissues. A small
proportion (30%) of precancer tissues also showed moderate STAT3
positivity (Figure 2A). Similarly, we examined pSTAT3 level to evaluate
the fraction of active STAT3 pool. The pSTAT3 level in lesions of dif-
ferent disease groups correlated pretty well with the STAT3 level
(Figure 2A,B). Immunohistochemistry and box plot analysis revealed
the distribution of differentially expressed STAT3 pools in various cel-
lular compartments in gastric tissues (Figure 2C,D). In agreement with
our immunoblotting data, we did not find STAT3 or pSTAT3 positivity
in either epithelial or stromal cell in the histologically normal tissues;
however, weak nuclear STAT3 and pSTAT3 positivities were noticed
in the tissues with H. pylori infection (Table S5). On the other hand, sig-
nificantly (P < .001) higher STAT3 expression was observed in precan-
cerous lesions compared with the normal tissues. Intestinal metaplasia
lesions showed moderate expression of STAT3, diffusely localized in
the cytoplasm of gastric gland cells, while in Dys lesions, similarmoderate STAT3 expression was observed, but STAT3 was localized
in both the nucleus and the cytoplasm. In Dys, STAT3 expression
was also detected in stromal cells (Figure 2C,D and Table S6).
The pSTAT3 immunostaining correlated well with the STAT3
localization within cellular compartments as well as among different
types of cells in respective tissues. Significantly (P < .001) higher
STAT3 and pSTAT3 immunopositivities were invariably detected in
both nucleus and cytoplasm of adenocarcinoma cells as compared to
precancerous and normal lesions (Figure 2C,D and Table S7).
The habit of tobacco chewing/smoking/alcoholism was signifi-
cantly associated with increased nuclear and cytoplasmic STAT3/
pSTAT3 positivity (Tables S6 and S7). However, both STAT3 and
pSTAT3 positivities (cytoplasmic and nuclear) invariably showed a
stronger correlation (P < .001) with H. pylori positivity not only in
adenocarcinoma lesions (Table S7) but also in all other grades of
tissues (Tables S5 and S6).
FIGURE 2 Expression of active STAT3 in different grades of gastric biopsies. A, Immunoblot analysis of STAT3 and pSTAT3 (Y705). Positive
control (Ctrl; HeLa cells), gastric adenocarcinoma cells (AGS) and freshly collected normal (N), intestinal metaplasia (IM), dysplasia (Dys), diffuse‐
type adenocarcinoma (DC), and intestinal‐type adenocarcinoma (IC). Blots were reprobed for β‐actin, which was used as an internal control. B,
Mean fold difference in the integrated densitometric values of bands in the immunoblots was calculated as described below after normalizing the
values to β‐actin. Error bars indicate standard deviation. *P value ≤ .001 vs normal for STAT3, #P value ≤ .01 vs normal for pSTAT3. C, Box plots
showing distribution of nuclear and cytoplasmic survivin total scores based on immunohistochemical analysis. Normal, Precancer, and Cancer.
Scoring was performed on the scale of 0 to 7 on percent positivity and intensity of staining as described in Section 2. The outlier samples with
their individual score represented as asterisk/dot. D, Representative photomicrograph of STAT3 and pSTAT3 immunohistochemical analysis. Well‐
differentiated IC (WD‐IC), moderately differentiated IC (MD‐IC). Black arrows = cytoplasmic expression; green arrows = nuclear expression
(original magnification, ×200)
6 of 11 PANDEY ET AL.3.3 | Evaluation of survivin, STAT3, and pSTAT3 as
diagnostic markers for precancerous states and
adenocarcinoma in gastric lesions
Receiver operating characteristic analysis was used to determine the
potential of survivin, STAT3, and pSTAT3 expressions to distinguish
precancerous and cancer lesions from normal gastric tissues. We
observed that cytoplasmic as well as nuclear expression of survivin,
STAT3, and pSTAT3 revealed significant differences between normal,
precancer, and gastric adenocarcinoma samples with increased area
under the curve (AUC) values (Figure 3A). Interestingly, the nuclear
survivin, STAT3, and pSTAT3 showed AUC values of 0.822, 0.800,
and 0.809 (P < .001) with a positive predictive value of 89.06, 89.66,
and 91.07, respectively, to discriminate between gastric precancer
and adenocarcinoma lesions (Figure 3B).3.4 | H. pylori infection is correlated with survivin,
STAT3, and pSTAT3 expressions in precancerous
lesions and adenocarcinomas
Subsequent assessment of subcellular localization of survivin, STAT3,
and active STAT3 in study samples with respect to their H. pylori sta-
tus revealed that survivin and active STAT3 were chiefly associated
with H. pylori positivity in both malignant and nonmalignant gastric
tissues (Table 2). The Pearson correlation was used to analyze the
variability of expressions of survivin, STAT3, and pSTAT3 by IHC
and PCR‐based detection of H. pylori infection in gastric tissues.
The expressions of ureC and cagA are congruent (r = 0.490,
P < .001) in all tissue samples (r = 0.516, P < .001). High concordance
was observed between the 2 PCR experiments in adenocarcinoma
tissues (Table S8).
FIGURE 3 The biomarker analysis of survivin, STAT3, and pSTAT3 in gastric precancer and cancer (adenocarcinoma) cases. A, The receiver
operating characteristic curves analysis of survivin, STAT3, and pSTAT3 protein expression. The reference line (small dotted line) showed 0.5
values of sensitivity and specificity. B, The biomarker analysis of survivin, STAT3, and pSTAT3 in different gastric pathologies. Values indicate
optimal sensitivity, specificity, positive predictive value (PPV), negative predictive values (NPV), and area under the curve (AUC) of the test at the
specified cutoff
PANDEY ET AL. 7 of 11The ureC expression was correlated with cytoplasmic survivin partic-
ularly in precancer and adenocarcinoma cases (r = 0.381, P = .038 and
r = 0.324, P < .01) (Table S8). The ureC positivity also showed a strong cor-
relation with STAT3 and pSTAT3 irrespective of their subcellular localiza-
tion in adenocarcinoma lesions. Similarly, cagA positivity was correlatedwith cytoplasmic localization of survivin and STAT3 in precancerous
lesions. Interestingly, cagA positivity was only strongly associated with
STAT3 and pSTAT3 positivities in adenocarcinomas. Interestingly,
survivin expression was found strongly associated with STAT3 and
pSTAT3 levels irrespective of their subcellular localization (Table S8).
T
A
B
LE
2
D
is
tr
ib
ut
io
n
o
f
su
rv
iv
in
,S
T
A
T
3
,a
nd
pS
T
A
T
3
in
di
ff
er
en
t
ga
st
ri
c
ti
ss
ue
ty
pe
s
w
it
h
re
sp
ec
t
to
th
e
st
at
us
o
f
H
el
ic
ob
ac
te
r
py
lo
ri
in
fe
ct
io
n
N
o
rm
al
(n
=
6
1
)
P
re
ca
nc
er
(n
=
3
0
)
C
an
ce
r
(n
=
6
5
)
T
o
ta
l
C
as
es
(n
=
1
5
6
)
H
.p
yl
or
iP
o
si
ti
ve
(%
)
H
.p
yl
or
i
N
eg
at
iv
e
(%
)
P V
al
ue
H
.p
yl
or
iP
o
si
ti
ve
(%
)
H
.p
yl
or
i
N
eg
at
iv
e
(%
)
P V
al
ue
H
.p
yl
or
iP
o
si
ti
ve
(%
)
H
.p
yl
or
i
N
eg
at
iv
e
(%
)
P V
al
u
e
H
.p
yl
or
iP
o
si
ti
ve
(%
)
H
.p
yl
or
i
N
eg
at
iv
e
(%
)
P V
al
u
e
C
as
es
(%
)
3
7
(6
0
.7
%
)
2
4
(3
9
.3
%
)
2
8
(9
3
.3
%
)
2
(0
.7
%
)
3
4
(5
2
.3
%
)
3
1
(4
7
.7
%
)
9
9
(6
3
.5
%
)
5
7
(3
6
.5
%
)
M
ar
ke
rs
a
Su
bc
el
lu
la
r
lo
ca
liz
at
io
n
Su
rv
iv
in
C
yt
o
pl
as
m
ic
(A
)
3
(8
.1
)
0
(0
)
.1
5
3
1
7
(6
0
.7
)
0
(0
)
.0
9
4
3
4
(1
0
0
)
2
5
(8
0
.6
)
.0
0
7
5
4
(5
4
.5
)
2
5
(4
3
.9
)
.1
9
9
N
uc
le
ar
(B
)
1
0
(2
7
)
0
(0
)
.0
0
5
7
(2
5
)
0
(0
)
.4
1
9
3
4
(1
0
0
)
2
3
(7
4
.2
)
.0
0
2
5
1
(5
1
.5
)
2
3
(4
0
.4
)
.1
7
9
B
o
th
(A
∩B
)
3
(8
.1
)
0
(0
)
.1
5
3
7
(2
5
)
0
(0
)
.4
1
9
3
4
(1
0
0
)
2
3
(7
4
.2
)
.0
0
2
4
4
(4
4
.4
)
2
3
(4
0
.4
)
.6
1
9
ST
A
T
3
C
yt
o
pl
as
m
ic
(A
)
0
(0
)
0
(0
)
…
9
(3
2
.1
)
0
(0
)
.3
3
8
3
3
(9
7
.1
)
1
2
(3
8
.7
)
≤
.0
0
1
4
2
(4
2
.4
)
1
2
(2
1
.1
)
.0
0
7
N
uc
le
ar
(B
)
5
(1
3
.5
)
0
(0
)
.0
6
0
6
(2
1
.4
)
0
(0
)
.4
6
4
3
4
(1
0
0
)
1
8
(5
8
.1
)
≤
.0
0
1
4
5
(4
5
.5
)
1
8
(3
1
.6
)
.0
8
9
B
o
th
(A
∩B
)
0
(0
)
0
(0
)
…
5
(1
7
.9
)
0
(0
)
.5
1
3
3
3
(9
7
.1
)
1
2
(3
8
.7
)
≤
.0
0
1
3
8
(3
8
.4
)
2
4
(2
1
.1
)
.0
2
6
pS
T
A
T
3
C
yt
o
pl
as
m
ic
(A
)
0
(0
)
0
(0
)
…
7
(2
5
)
0
(0
)
.4
1
9
3
3
(9
7
.1
)
1
0
(3
2
.3
)
≤
.0
0
1
4
0
(4
0
.4
)
1
0
(1
7
.5
)
.0
0
3
N
uc
le
ar
(B
)
0
(0
)
1
(2
.7
)
.4
1
7
5
(1
7
.9
)
0
(0
)
.5
1
3
3
4
(1
0
0
)
1
7
(5
4
.8
)
≤
.0
0
1
4
0
(4
0
.4
)
1
7
(2
9
.8
)
.1
8
6
B
o
th
(A
∩B
)
0
(0
)
0
(0
)
…
4
(1
4
.3
)
0
(0
)
.5
6
6
3
3
(9
7
.1
)
1
0
(3
2
.3
)
≤
.0
0
1
3
7
(3
7
.4
)
1
0
(1
7
.5
)
.0
0
9
B
o
ld
em
ph
as
iz
e
st
at
is
ti
ca
lly
si
gn
if
ic
an
t.
a T
he
ti
ss
ue
se
ct
io
ns
w
er
e
sc
o
re
d
o
n
th
e
sc
al
e
o
f
0
to
7
ba
se
d
o
n
th
e
p
er
ce
nt
ag
e
o
f
im
m
un
o
st
ai
ne
d
ce
lls
as
<
1
0
%
=
0
;
1
0
‐3
0
%
=
1
;
3
0
‐5
0
%
=
2
;
5
0
‐7
0
%
=
3
;
an
d
7
0
‐1
0
0
%
=
4
.
Se
ct
io
n
s
w
er
e
al
so
sc
o
re
d
se
m
iq
u
an
-
ti
ta
ti
ve
ly
o
n
th
e
ba
si
s
o
f
st
ai
ni
ng
in
te
ns
it
y
as
no
‐s
ta
in
=
0
;
m
ild
=
1
;
m
o
d
er
at
e
=
2
;
an
d
in
te
ns
e
=
3
.S
ec
ti
o
ns
w
er
e
co
ns
id
er
ed
po
si
ti
ve
w
he
n
to
ta
l
sc
o
re
w
as
≥
2
fo
r
su
rv
iv
in
an
d
≥
3
fo
r
ST
A
T
3
an
d
p
ST
A
T
3
.
8 of 11 PANDEY ET AL.4 | DISCUSSION
We observed overexpression of survivin and STAT3 proteins during
gastric tumor progression, specifically cytoplasmic survivin along with
nuclear pSTAT3 in gastric precancerous lesions. A strong correlation
was observed between H. pylori positivity as measured by PCR‐based
detection of its 2 key genes, cagA and ureC, with survivin and STAT3
expression present in different subcellular compartments.
Our results revealed the absence of survivin in normal tissues and
significant survivin expression in both premalignant and cancerous
lesions. Previous studies established survivin as an apoptosis‐associ-
ated marker in different gastric tissue types.11,13,14,27 Interestingly,
these studies showed complete lack of survivin expression in normal
gastric tissues. In contrast, we observed a low to moderate expression
of survivin in normal gastric tissues. These discrepancies can be
explained due to likely region‐specific variation in H. pylori strains as
well as genetic and epigenetic variation in the patient population.
Our observations imply the potential involvement of survivin in gastric
cancer progression. The IHC analysis revealed differential expression
of survivin in gastric lesions. The precancerous lesions expressed
survivin predominantly in the cytoplasmic compartment, compared
with advanced malignant lesions with nuclear and cytoplasmic expres-
sion. Subcellular distribution of survivin thus may be a dynamic pro-
cess that may function as a switch cells between proliferative and
prosurvival phase, possibly reflecting survivin's distinct functions in
different cellular compartments.16 Based on its antiapoptotic role in
the cytoplasm, it is likely that cytoplasmic survivin dominantly seen
in precancer lesions assists in preventing cell death and imparting
chemoresistance in cells in these lesions, whereas nuclear survivin in
adenocarcinomas may help stimulate cell division frequently observed
in advanced malignant lesions. These assumptions are supported by
observation indicating that nuclear localization of survivin reduces its
stability and is not cytoprotective,28,29 which makes tumor cell more
sensitive to antitumor drugs.30 A similar context, survivin expression
in tumor cell nuclei has been proposed to be the predictor of favorable
prognosis11 that strongly suggests contrasting functional outcome of
differentially localized survivin.
It is interesting to note in this context that tobacco usage is
strongly associated with nuclear survivin in all tissues of test subjects
indicating a potential contribution of tobacco use habit to tumor cell
proliferation as observed in hepatocellular carcinoma.31 However, this
effect may not be limited to nuclear survivin as the cytoplasmic pool
was also found significantly upregulated in tumor tissues of tobacco
users suggesting an overall increase of survivin. Studies on normal
human bronchial epithelial cells revealed a specific upregulation of
survivin due to tobacco exposure.32
We observed an association between cagA DNA positivity and
cytoplasmic survivin particularly in histopathologically normal and in
precancerous tissues. CagA activates survivin expression via activation
of the STAT3 pathway,21 which in concert with survivin promotes gas-
tric cell survival.20 Interestingly, cells incapable of overexpressing
survivin underwent apoptotic death at a very early stage33 through
γ‐glutamyl transpeptidase activity that leads to proteasome‐mediated
degradation of survivin.34 These observations suggest a strong
prosurvival axis mediated by cagA that is manifested through active
PANDEY ET AL. 9 of 11STAT3 and survivin, which, if located in the cytoplasm, may impart
cytoprotection to precancerous cells during the early phase of gastric
carcinogenesis.
Based on above evidence, we investigated corresponding levels of
the pSTAT3 (Y705) that represents the active state of the transcrip-
tion factor in gastric lesions along with survivin. Interestingly,
increased expression of STAT3 and pSTAT3 was significantly associ-
ated with the severity of the lesions. The result of IHC using STAT3
or pSTAT3 with respect to overall expression or subcellular distribu-
tion resembled but was not concordant in each case. The discordance
could be primarily due to the differential affinity of antigen‐antibody
interaction but also due to the possibility of the noncanonical pres-
ence of unphosphorylated STAT3 in the nuclei.35 It is also possible
that pSTAT3 is present in the cytoplasm as well.36,37 Nevertheless, a
strong concordance of STAT3 with survivin confirms its transcriptional
regulatory role in upregulation of survivin in gastric carcinogenesis, as
proposed earlier.20
Interestingly, stromal cells in dysplastic lesions also showed mod-
erate positivity for active STAT3 and survivin, which was absent in IM
or normal gastric mucosa. Appearance of active STAT3 and conse-
quently the expression of survivin in stromal cells indicate towards
establishment of a cooperative tumor‐promoting interaction of gastric
tumor cells with its microenvironment through autocrine/paracrine
stimulation. Gastric cancer cells have been shown to secrete PGE2
and tumor necrosis factor α that stimulate production of IL‐6 via stro-
mal cells,38 which by itself activates STAT3 in stromal fibroblasts.39
Earlier studies established the presence of active STAT3 in human
gastric precancerous and cancer tissues,40 in an animal model,21,41 and
also in cancer cell lines.20 Active STAT3 has been associated with
lymph node metastasis42 and poor prognosis in gastric cancer
patients.43 Aberrant activation of STAT3 is shown to be mediated by
IL‐6/IL‐11–dependent44 or IL‐6–independent mechanism by the
direct action of cagA on ligand‐independent gp130 activation,44 loss
of its feedback inhibitors SOCS‐2/SOCS‐3, or through direct activa-
tion by EFGR.45 Incidentally, we observed a strong correlation
between H. pylori positivity and STAT3 or pSTAT3 irrespective of their
subcellular location. Although H. pylori infection may not be essential
in advanced gastric lesions as seen in the present study, our observa-
tions suggest that the presence of concurrent H. pylori infection may
assist tumor cells in maintenance of high level of STAT3/pSTAT3. This
assumption was further supported by the presence of nuclear STAT3
in H. pylori‐positive normal tissues.
Apart from H. pylori infection, the habits of tobacco or alcohol
abuse were also found associated with STAT3 localized to the nuclei
of precancer and cancer tissues. Activation of STAT3 has been dem-
onstrated in tobacco chewing–mediated oral carcinogenesis earlier46
whereas tobacco smoke induces IL‐6/STAT3 pathways in lung
tissues.47 However, there is no evidence to date that suggests any
relation of tobacco habit with STAT3 levels in gastric cancer. Similarly,
habit of alcohol abuse also correlated with high levels of STAT3. Alco-
hol consumption and smoking are considered risk factor for gastric
cancer.48 However, link of alcohol use habit with active STAT3 in
our study and its association with gastric carcinogenesis depicted in
previous studies are indicative of an association that needs future
investigation.Some studies that have coevaluated overall survivin and STAT3
in gastric tissues49-51 or in experimental model20 lacked the detailed
analysis in regard to the subcellular distribution of survivin. It was
interesting to note that correlation coefficients were significantly
lower in precancer lesions indicating a subset of tissues with prefer-
ential localization of survivin in one compartment. Despite strong
correlation with each other, survivin and STAT3/pSTAT3 showed
differential expression and variable subcellular localization in
different gastric lesions. Therefore, to understand the disease
grade‐specific expression characteristics in different cellular pools,
we reexamined our IHC data for marker analysis. Receiver operating
characteristic curves for survivin, STAT3, and pSTAT3 in the differ-
ent subcellular pool, which demonstrated high AUC values, and low
cutoff value distinguished the level of expression among different
tissue types. To the best of our knowledge, this is the first attempt
to evaluate the subcellular content of survivin and STAT3 as a
marker in gastric carcinogenesis. These observations along with
reports from other investigators52-55 suggest the role of survivin
and active nuclear STAT3 in gastric cancer progression.5 | CONCLUSIONS
Despite a small sample size and a cross‐sectional study, present inves-
tigation demonstrates overexpression of survivin and STAT3 in gastric
cancer that correlated with increasing severity of the gastric lesions.
The specific increase in cytoplasmic survivin together with enhanced
nuclear pSTAT3 in gastric precancerous cells and diffused overexpres-
sion of survivin and STAT3 in cancer lesions was observed. Survivin
and STAT3 levels were also highly correlated with concurrent H. pylori
infection. Survivin and STAT3 are key players in promoting carcino-
genesis and mediating the intrinsic/primary chemoresistance.56,57
Hence, these proteins could be suitable therapeutic targets in
preventing gastric cancer progression. However, further follow‐up
studies are needed to validate clinical utility of survivin and STAT3
as prognostic markers.
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